Esther C W Breij (Esther Cw Breij)

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 7

Top Topics

Monoclonal Antibody

Acute Lymphoblastic Leukemia

Top Venues

Blood cancer journal

Journal of immunology (Baltimore, Md. : 1950)

Molecular cancer therapeutics

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Jantine E Bakema, Marijke Stigter van Walsum, Jeffrey R Harris, Sonja H Ganzevles, Anantharaman Muthuswamy, Mischa Houtkamp, Theo S Plantinga, Elisabeth Bloemena, Ruud H Brakenhoff, Esther C W Breij, Rieneke van de Ven
An antibody-drug conjugate directed to tissue factor shows preclinical anti-tumor activity in head and neck cancer as a single agent and in combination with chemoradiotherapy. Molecular cancer therapeutics (2023)
Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva, Eytan Ben-Ami, Corinne Maurice-Dror, Emiliano Calvo, Patricia M LoRusso, Guzman Alonso, Maria E Rodriguez-Ruiz, Kristina B Schoedel, Jordan M Blum, Bianca Sänger, Theodora W Salcedo, Saskia M Burm, Eliana Stanganello, Dennis Verzijl, Fulvia Vascotto, Angelica Sette, Juliane Quinkhardt, Theo S Plantinga, Aras Toker, Edward N van den Brink, Mark Fereshteh, Mustafa Diken, David Satijn, Sebastian Kreiter, Esther C W Breij, Gaurav Bajaj, Eleni Lagkadinou, Kate Sasser, Özlem Türeci, Ulf Forssmann, Tahamtan Ahmadi, Uğur Şahin, Maria Jure-Kunkel, Ignacio Melero Bermejo
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer discovery 12 (5) (2022)
Kristel Kemper, Ellis Gielen, Peter Boross, Mischa Houtkamp, Theo S Plantinga, Stefanie Ah de Poot, Saskia M Burm, Maarten L Janmaat, Louise A Koopman, Edward N van den Brink, Rik Rademaker, Dennis Verzijl, Patrick J Engelberts, David Satijn, A Kate Sasser, Esther C W Breij
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models. Life science alliance 5 (11) (2022)
Hilma J van der Horst, A Vera de Jonge, Ida H Hiemstra, Anne T Gelderloos, Daniella R A I Berry, Nathalie J Hijmering, Hendrik F van Essen, Daphne de Jong, Martine E D Chamuleau, Sonja Zweegman, Esther C W Breij, Margaretha G M Roemer, Tuna Mutis
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood cancer journal 11 (2) (2021)
Simone C Oostindie, Hilma J van der Horst, Laurens P Kil, Kristin Strumane, Marije B Overdijk, Edward N van den Brink, Jeroen H N van den Brakel, Hendrik J Rademaker, Berris van Kessel, Juliette van den Noort, Martine E D Chamuleau, Tuna Mutis, Margaret A Lindorfer, Ronald P Taylor, Janine Schuurman, Paul W H I Parren, Frank J Beurskens, Esther C W Breij
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood cancer journal 10 (3) (2020)
Patrick J Engelberts, Esther C W Breij, Thomas Valerius, Janine Schuurman, Paul W H I Parren, Frank J Beurskens
Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells". Journal of immunology (Baltimore, Md. : 1950) 200 (8) (2019)
Patrick J Engelberts, Marleen Voorhorst, Janine Schuurman, Tom van Meerten, Joost M Bakker, Tom Vink, Wendy J M Mackus, Esther C W Breij, Stefanie Derer, Thomas Valerius, Jan G J van de Winkel, Paul W H I Parren, Frank J Beurskens
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. Journal of immunology (Baltimore, Md. : 1950) 197 (12) (2016)